CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Heart Failure With Preserved Ejection Fraction in the Young Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study

Review Article2017 Jun 13;69(23):2845-2861.

JOURNAL:J Am Coll Cardiol. Article Link

Left Ventricular Assist Devices for Lifelong Support

Pinney SP, Anyanwu AC, Lala A et al. Keywords: cardiothoracic surgery; heart failure; hemocompatibility

ABSTRACT


Continuous-flow left ventricular assist devices (LVADs) have revolutionized advanced heart failure care. These compact, fully implantable heart pumps are capable of providing meaningful increases in survival, functional capacity, and quality of life. Implantation volumes continue to grow, but several challenges remain to be overcome before LVADs will be considered as the therapy of choice for all patients with advanced heart failure. They must be able to consistently extend survival for the long term (7 to 10 years), rather than the midterm (3 to 5 years) more typical of contemporary devices; they must incorporate design elements that reduce shear stress and avoid stasis to reduce the frequent adverse events of bleeding, stroke, and pump thrombosis; and they must become more cost-effective. The advancements in engineering, implantation technique, and medical management detailed in this review will highlight the progress made toward achieving lifelong LVAD support and the challenges that remain.